Collagen Autoantibodies and Their Relationship to CCP Antibodies and Rheumatoid Factor in the Progression of Early Rheumatoid Arthritis
Abstract
:1. Introduction
2. Results
2.1. Frequency of Autoantibodies to CB10 in Established RA
2.2. Autoantibodies to CB10 in Early RA
2.3. Anti-CCP in Early Inflammatory Arthritis
2.4. Rheumatoid Factor in Early Inflammatory Arthritis
2.5. Predictive Value of Autoantibodies
2.6. Sequential Changes in Autoantibodies
3. Discussion
4. Materials and Methods
4.1. Patients
4.2. Preparation of CB10
4.3. Detection of Antibodies to CB10 by ELISA
4.4. Measurement of Autoantibodies to Citrullinated Protein Antigens
4.5. Measurement of RF
4.6. Statistical Analysis
5. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Arnett, F.C.; Edworthy, S.M.; Bloch, D.A.; McShane, D.J.; Fries, J.F.; Cooper, N.S.; Healey, L.A.; Kaplan, S.R.; Liang, M.H.; Luthra, H.S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988, 31, 315–324. [Google Scholar] [CrossRef] [PubMed]
- Berglin, E.; Dahlqvist, S.R. Comparison of the 1987 ACR and 2010 ACR/EULAR classification criteria for rheumatoid arthritis in clinical practice: A prospective cohort study. Scand. J. Rheumatol. 2013, 42, 362–368. [Google Scholar] [CrossRef] [PubMed]
- Van der Heijde, D.; van der Helm-van Mil, A.H.M.; Aletaha, D.; Bingham, C.O.; Burmester, G.R.; Dougados, M.; Emery, P.; Felson, D.; Knevel, R.; Kvien, T.K.; et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann. Rheum. Dis. 2013, 72, 479–481. [Google Scholar] [CrossRef] [PubMed]
- Ropes, M.W.; Bennett, G.A.; Cobb, S.; Jacox, R.; Jessar, R.A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull. Rheum. Dis. 1958, 9, 175–176. [Google Scholar] [PubMed]
- Aho, K.; Heliövaara, M.; Maatela, J.; Tuomi, T.; Palosuo, T. Rheumatoid factors antedating clinical rheumatoid arthritis. J. Rheumatol. 1991, 18, 1282–1284. [Google Scholar] [PubMed]
- Pekin, T.J.; Zvaifler, N.J. Hemolytic Complement in Synovial Fluid. J. Clin. Investig. 1964, 43, 1372–1382. [Google Scholar] [CrossRef] [PubMed]
- Halla, J.T.; Volanakis, J.E.; Schrohenloher, R.E. Immune complexes in rheumatoid arthritis sera and synovial fluids: A comparison of three methods. Arthritis Rheum. 1979, 22, 440–448. [Google Scholar] [CrossRef] [PubMed]
- Luthra, H.S.; McDuffie, F.C.; Hunder, G.G.; Samayoa, E.A. Immune complexes in sera and synovial fluids of patients with rheumatoid arthritis. Radioimmunoassay with monoclonal rheumatoid factor. J. Clin. Investig. 1975, 56, 458. [Google Scholar] [CrossRef] [PubMed]
- Menzel, J.; Steffen, C.; Kolarz, G.; Eberal, G.; Frank, O.; Thumb, N. Demonstration of antibodies to collagen and of collagen-anticollagen immune complexes in rheumatoid arthritis synovial fluids. Ann. Rheum. Dis. 1975, 35, 446–450. [Google Scholar] [CrossRef] [PubMed]
- Roberts-Thomson, P.J.; Neoh, S.H.; Bradley, J.; Milazzo, S.C. Circulating and intra-articular immune complexes in rheumatoid arthritis: A comparative study of the C1q binding and monoclonal rheumatoid factor assays. Ann. Rheum. Dis. 1980, 39, 438–444. [Google Scholar] [CrossRef] [PubMed]
- Winchester, R.J.; Agnello, V.; Kunkel, H.G. Gamma globulin complexes in synovial fluids of patients with rheumatoid arthritis. Partial characterization and relationship to lowered complement levels. Clin. Exp. Immunol. 1970, 6, 689–706. [Google Scholar] [PubMed]
- Aho, K.; Konttinen, A.; Rajasalmi, M.; Wager, O. Transient appearance of the rheumatoid factor in connection with prophylactic vaccinations. Acta Pathol. Microbiol. Scand. 1962, 56, 478–479. [Google Scholar] [CrossRef] [PubMed]
- Carson, D.A.; Chen, P.P.; Fox, R.I.; Kipps, T.J.; Jirik, F.; Goldfien, R.D.; Silverman, G.; Radoux, V.; Fong, S. Rheumatoid factor and immune networks. Annu. Rev. Immunol. 1987, 5, 109–126. [Google Scholar] [CrossRef] [PubMed]
- Nowak, U.M.; Newkirk, M.M. Rheumatoid factors: Good or bad for you? Int. Arch. Allergy Immunol. 2005, 138, 180–188. [Google Scholar] [CrossRef] [PubMed]
- Jilani, A.A.; Mackworth-Young, C.G. The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: A systematic literature review and meta-analysis. Int. J. Rheumatol. 2015, 2015, 728610. [Google Scholar] [CrossRef] [PubMed]
- Spengler, J.; Lugonja, B.; Jimmy Ytterberg, A.; Zubarev, R.A.; Creese, A.J.; Pearson, M.J.; Grant, M.M.; Milward, M.; Lundberg, K.; Buckley, C.D.; et al. Release of active peptidyl arginine deiminases by neutrophils can explain production of extracellular citrullinated autoantigens in rheumatoid arthritis synovial fluid: Enzymatically active PADs and autoantigen production in RA SF. Arthritis Rheumatol. 2015, 67, 3135–3145. [Google Scholar] [CrossRef] [PubMed]
- Levesque, M.C.; Zhou, Z.; Moreland, L.W. Anti-cyclic citrullinated peptide testing for the diagnosis of rheumatoid arthritis and the quest for improved sensitivity and predictive value. Arthritis Rheum. 2009, 60, 2211–2215. [Google Scholar] [CrossRef] [PubMed]
- Goules, J.D.; Goules, A.V.; Tzioufas, A.G. Fine specificity of anti-citrullinated peptide antibodies discloses a heterogeneous antibody population in rheumatoid arthritis. Clin. Exp. Immunol. 2013, 174, 10–17. [Google Scholar] [CrossRef] [PubMed]
- Snir, O.; Widhe, M.; von Spee, C.; Lindberg, J.; Padyukov, L.; Lundberg, K.; Engström, A.; Venables, P.J.; Lundeberg, J.; Holmdahl, R.; et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: Association with HLA-DRB1 alleles. Ann. Rheum. Dis. 2009, 68, 736–743. [Google Scholar] [CrossRef] [PubMed]
- Tsuda, R.; Ozawa, T.; Kobayashi, E.; Hamana, H.; Taki, H.; Tobe, K.; Sugiyama, E.; Iwamoto, M.; Imura, J.; Kishi, H.; et al. Monoclonal antibody against citrullinated peptides obtained from rheumatoid arthritis patients reacts with numerous citrullinated microbial and food proteins: Reactivity of ACPA with citrullinated autoantigens in RA. Arthritis Rheumatol. 2015, 67, 2020–2031. [Google Scholar] [CrossRef] [PubMed]
- Brink, M.; Hansson, M.; Mathsson, L.; Jakobsson, P.-J.; Holmdahl, R.; Hallmans, G.; Stenlund, H.; Rönnelid, J.; Klareskog, L.; Rantapää-Dahlqvist, S. Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis: Frequency of ACPAs before and after RA onset. Arthritis Rheum. 2013, 65, 899–910. [Google Scholar] [CrossRef] [PubMed]
- Johansson, L.; Pratesi, F.; Brink, M.; Ärlestig, L.; D’Amato, C.; Bartaloni, D.; Migliorini, P.; Rantapää-Dahlqvist, S. Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis. Arthritis Res. Ther. 2016, 18. [Google Scholar] [CrossRef] [PubMed]
- Rantapää-Dahlqvist, S.; de Jong, B.A.W.; Berglin, E.; Hallmans, G.; Wadell, G.; Stenlund, H.; Sundin, U.; van Venrooij, W.J. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003, 48, 2741–2749. [Google Scholar] [CrossRef] [PubMed]
- Ossipova, E.; Cerqueira, C.F.; Reed, E.; Kharlamova, N.; Israelsson, L.; Holmdahl, R.; Nandakumar, K.S.; Engström, M.; Harre, U.; Schett, G.; et al. Affinity purified anti-citrullinated protein/peptide antibodies target antigens expressed in the rheumatoid joint. Arthritis Res. Ther. 2014, 16, R167. [Google Scholar] [CrossRef] [PubMed]
- Vossenaar, E.R.; Smeets, T.J.M.; Kraan, M.C.; Raats, J.M.; van Venrooij, W.J.; Tak, P.P. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 2004, 50, 3485–3494. [Google Scholar] [CrossRef] [PubMed]
- Ronnelid, J. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: Anti-CP status predicts worse disease activity and greater radiological progression. Ann. Rheum. Dis. 2005, 64, 1744–1749. [Google Scholar] [CrossRef] [PubMed]
- Bassyouni, I.H.; Ezzat, Y.; Hamdy, S.; Talaat, R.M. Clinical significance of anti-cyclic citrullinated peptide antibodies in Egyptian patients with chronic hepatitis C virus genotype IV infection. Clin. Chem. Lab. Med. 2009, 47, 842–847. [Google Scholar] [CrossRef] [PubMed]
- Fischer, A.; Solomon, J.J.; du Bois, R.M.; Deane, K.D.; Olson, A.L.; Fernandez-Perez, E.R.; Huie, T.J.; Stevens, A.D.; Gill, M.B.; Rabinovitch, A.M.; et al. Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease. Respir. Med. 2012, 106, 1040–1047. [Google Scholar] [CrossRef] [PubMed]
- Singh, U.; Singh, S.; Singh, N.K.; Verma, P.K.; Singh, S. Anticyclic citrullinated peptide autoantibodies in systemic lupus erythematosus. Rheumatol. Int. 2011, 31, 765–767. [Google Scholar] [CrossRef] [PubMed]
- Gregersen, P.K.; Silver, J.; Winchester, R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987, 30, 1205–1213. [Google Scholar] [CrossRef] [PubMed]
- Scally, S.W.; Petersen, J.; Law, S.C.; Dudek, N.L.; Nel, H.J.; Loh, K.L.; Wijeyewickrema, L.C.; Eckle, S.B.G.; van Heemst, J.; Pike, R.N.; et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 2013, 210, 2569–2582. [Google Scholar] [CrossRef] [PubMed]
- Steffen, C. Consideration of pathogenesis of rheumatoid arthritis as collagen autoimmunity. Z. Für Immun. Allerg. Klin. Immunol. 1970, 139, 219–227. [Google Scholar]
- Fujii, K.; Tsuji, M.; Kitamura, A.; Murota, K. The diagnostic significance of anti-type II collagen antibody assay in rheumatoid arthritis. Int. Orthop. 1992, 16, 272–276. [Google Scholar] [CrossRef] [PubMed]
- Pereira, R.S.; Black, C.M.; Duance, V.C.; Jones, V.E.; Jacoby, R.K.; Welsh, K.I. Disappearing collagen antibodies in rheumatoid arthritis. Lancet Lond. Engl. 1985, 2, 501–502. [Google Scholar] [CrossRef]
- Cook, A.D.; Rowley, M.J.; Mackay, I.R.; Gough, A.; Emery, P. Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum. 1996, 39, 1720–1727. [Google Scholar] [CrossRef] [PubMed]
- Lindh, I.; Snir, O.; Lönnblom, E.; Uysal, H.; Andersson, I.; Nandakumar, K.S.; Vierboom, M.; ’t Hart, B.; Malmström, V.; Holmdahl, R. Type II collagen antibody response is enriched in the synovial fluid of rheumatoid joints and directed to the same major epitopes as in collagen induced arthritis in primates and mice. Arthritis Res. Ther. 2014, 16, R143. [Google Scholar] [CrossRef] [PubMed]
- Steffen, C.; Ludwig, H.; Knapp, W. Collagen-anticollagen immune complexes in rheumatoid arthritis synovial fluid cells. Z. Für Immun. Exp. Klin. Immunol. 1974, 147, 229–235. [Google Scholar]
- Clague, R.B.; Moore, L.J. IgG and IgM antibody to native type II collagen in rheumatoid arthritis serum and synovial fluid. Evidence for the presence of collagen-anticollagen immune complexes in synovial fluid. Arthritis Rheum. 1984, 27, 1370–1377. [Google Scholar] [CrossRef] [PubMed]
- Trentham, D.E.; Townes, A.S.; Kang, A.H. Autoimmunity to type II collagen an experimental model of arthritis. J. Exp. Med. 1977, 146, 857–868. [Google Scholar] [CrossRef] [PubMed]
- Courtenay, J.S.; Dallman, M.J.; Dayan, A.D.; Martin, A.; Mosedale, B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 1980, 283, 666–668. [Google Scholar] [CrossRef] [PubMed]
- Wooley, P.H.; Luthra, H.S.; Stuart, J.M.; David, C.S. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J. Exp. Med. 1981, 154, 688–700. [Google Scholar] [CrossRef] [PubMed]
- Svensson, L.; Jirholt, J.; Holmdahl, R.; Jansson, L. B cell-deficient mice do not develop type II collagen-induced arthritis (CIA). Clin. Exp. Immunol. 1998, 111, 521–526. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Kristan, J.; Hao, L.; Lenkoski, C.S.; Shen, Y.; Matis, L.A. A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis. J. Immunol. 2000, 164, 4340–4347. [Google Scholar] [CrossRef] [PubMed]
- Burkhardt, H.; Koller, T.; Engström, A.; Nandakumar, K.S.; Turnay, J.; Kraetsch, H.G.; Kalden, J.R.; Holmdahl, R. Epitope-specific recognition of type II collagen by rheumatoid arthritis antibodies is shared with recognition by antibodies that are arthritogenic in collagen-induced arthritis in the mouse. Arthritis Rheum. 2002, 46, 2339–2348. [Google Scholar] [CrossRef] [PubMed]
- Kraetsch, H.G.; Unger, C.; Wernhoff, P.; Schneider, C.; Kalden, J.R.; Holmdahl, R.; Burkhardt, H. Cartilage-specific autoimmunity in rheumatoid arthritis: Characterization of a triple helical B cell epitope in the integrin-binding-domain of collagen type II. Eur. J. Immunol. 2001, 31, 1666–1673. [Google Scholar] [CrossRef]
- Nandakumar, K.S.; Bajtner, E.; Hill, L.; Böhm, B.; Rowley, M.J.; Burkhardt, H.; Holmdahl, R. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum. 2008, 58, 184–196. [Google Scholar] [CrossRef] [PubMed]
- Wernhoff, P.; Unger, C.; Bajtner, E.; Burkhardt, H.; Holmdahl, R. Identification of conformation-dependent epitopes and V gene selection in the B cell response to type II collagen in the DA rat. Int. Immunol. 2001, 13, 909–919. [Google Scholar] [CrossRef] [PubMed]
- Nandakumar, K.S.; Svensson, L.; Holmdahl, R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: Description of the disease and the influence of age, sex, and genes. Am. J. Pathol. 2003, 163, 1827–1837. [Google Scholar] [CrossRef]
- Burkhardt, H.; Sehnert, B.; Bockermann, R.; Engström, A.; Kalden, J.R.; Holmdahl, R. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis. Eur. J. Immunol. 2005, 35, 1643–1652. [Google Scholar] [CrossRef] [PubMed]
- Uysal, H.; Nandakumar, K.S.; Kessel, C.; Haag, S.; Carlsen, S.; Burkhardt, H.; Holmdahl, R. Antibodies to citrullinated proteins: Molecular interactions and arthritogenicity. Immunol. Rev. 2010, 233, 9–33. [Google Scholar] [CrossRef] [PubMed]
- Cook, A.D.; Gray, R.; Ramshaw, J.; Mackay, I.R.; Rowley, M.J. Antibodies against the CB10 fragment of type II collagen in rheumatoid arthritis. Arthritis Res. Ther. 2004, 6, R477–R483. [Google Scholar] [CrossRef] [PubMed]
- Stockman, A.; Tait, B.D.; Wolfe, R.; Brand, C.A.; Rowley, M.J.; Varney, M.D.; Buchbinder, R.; Muirden, K.D. Clinical, laboratory and genetic markers associated with erosions and remission in patients with early inflammatory arthritis: A prospective cohort study. Rheumatol. Int. 2006, 26, 500–509. [Google Scholar] [CrossRef] [PubMed]
- Laki, J.; Lundström, E.; Snir, O.; Rönnelid, J.; Ganji, I.; Catrina, A.I.; Bengtsson, C.; Saevarsdottir, S.; Wick, M.C.; Alfredsson, L.; et al. Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis. Arthritis Rheum. 2012, 64, 2078–2084. [Google Scholar] [CrossRef] [PubMed]
- Viatte, S.; Plant, D.; Raychaudhuri, S. Genetics and epigenetics of rheumatoid arthritis. Nat. Rev. Rheumatol. 2013, 9, 141–153. [Google Scholar] [CrossRef] [PubMed]
- Rowley, M.J.; Nandakumar, K.S.; Holmdahl, R. The role of collagen antibodies in mediating arthritis. Mod. Rheumatol. Jpn. Rheum. Assoc. 2008, 18, 429–441. [Google Scholar] [CrossRef]
- Mullazehi, M.; Mathsson, L.; Lampa, J.; Rönnelid, J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann. Rheum. Dis. 2007, 66, 537–541. [Google Scholar] [PubMed]
- Jasin, H.E. Autoantibody specificities of immune complexes sequestered in articular cartilage of patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1985, 28, 241–248. [Google Scholar] [CrossRef] [PubMed]
- Fehr, T.; Bachmann, M.F.; Bucher, E.; Kalinke, U.; di Padova, F.E.; Lang, A.B.; Hengartner, H.; Zinkernagel, R.M. Role of repetitive antigen patterns for induction of antibodies against antibodies. J. Exp. Med. 1997, 185, 1785–1792. [Google Scholar] [CrossRef] [PubMed]
- Christensen, A.D.; Haase, C.; Cook, A.D.; Hamilton, J.A. K/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory Arthritis. Front. Immunol. 2016, 7. [Google Scholar] [CrossRef] [PubMed]
- Wright, H.L.; Moots, R.J.; Edwards, S.W. The multifactorial role of neutrophils in rheumatoid arthritis. Nat. Rev. Rheumatol. 2014, 10, 593–601. [Google Scholar] [CrossRef] [PubMed]
- Kinloch, A.; Lundberg, K.; Wait, R.; Wegner, N.; Lim, N.H.; Zendman, A.J.W.; Saxne, T.; Malmström, V.; Venables, P.J. Synovial fluid is a site of citrullination of autoantigens in inflammatory arthritis. Arthritis Rheum. 2008, 58, 2287–2295. [Google Scholar] [CrossRef] [PubMed]
- Van der Helm-van Mil, A.H.M.; Verpoort, K.N.; Breedveld, F.C.; Huizinga, T.W.J.; Toes, R.E.M.; de Vries, R.R.P. The HLA–DRB1 shared epitope alleles are primarily a risk factor for anti–cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 2006, 54, 1117–1121. [Google Scholar] [CrossRef] [PubMed]
- Renner, N.; Krönke, G.; Rech, J.; Uder, M.; Janka, R.; Lauer, L.; Paul, D.; Herz, B.; Schlechtweg, P.; Hennig, F.F.; et al. Brief report: Anti-citrullinated protein antibody positivity correlates with cartilage damage and proteoglycan levels in patients with rheumatoid arthritis in the hand joints: ACPAs and cartilage damage in RA. Arthritis Rheumatol. 2014, 66, 3283–3288. [Google Scholar] [CrossRef] [PubMed]
- Maccioni, M.; Zeder-Lutz, G.; Huang, H.; Ebel, C.; Gerber, P.; Hergueux, J.; Marchal, P.; Duchatelle, V.; Degott, C.; van Regenmortel, M.; et al. Arthritogenic Monoclonal antibodies from K/BxN mice. J. Exp. Med. 2002, 195, 1071–1077. [Google Scholar] [CrossRef] [PubMed]
- Nandakumar, K.S.; Holmdahl, R. Efficient promotion of collagen antibody induced arthritis (CAIA) using four monoclonal antibodies specific for the major epitopes recognized in both collagen induced arthritis and rheumatoid arthritis. J. Immunol. Methods 2005, 304, 126–136. [Google Scholar] [CrossRef] [PubMed]
- Amirahmadi, S.F.; Pho, M.H.; Gray, R.E.; Crombie, D.E.; Whittingham, S.F.; Zuasti, B.B.; van Damme, M.-P.; Rowley, M.J. An arthritogenic monoclonal antibody to type II collagen, CII-C1, impairs cartilage formation by cultured chondrocytes. Immunol. Cell Biol. 2004, 82, 427–434. [Google Scholar] [CrossRef] [PubMed]
- Amirahmadi, S.F.; Whittingham, S.; Crombie, D.E.; Nandakumar, K.S.; Holmdahl, R.; Mackay, I.R.; van Damme, M.-P.; Rowley, M.J. Arthritogenic anti-type II collagen antibodies are pathogenic for cartilage-derived chondrocytes independent of inflammatory cells. Arthritis Rheum. 2005, 52, 1897–1906. [Google Scholar] [CrossRef] [PubMed]
- Croxford, A.M.; Crombie, D.; McNaughton, D.; Holmdahl, R.; Nandakumar, K.S.; Rowley, M.J. Specific antibody protection of the extracellular cartilage matrix against collagen antibody-induced damage. Arthritis Rheum. 2010, 62, 3374–3384. [Google Scholar] [CrossRef] [PubMed]
- Croxford, A.M.; Nandakumar, K.S.; Holmdahl, R.; Tobin, M.J.; McNaughton, D.; Rowley, M.J. Chemical changes demonstrated in cartilage by synchrotron infrared microspectroscopy in an antibody-induced murine model of rheumatoid arthritis. J. Biomed. Opt. 2011, 16, 66004. [Google Scholar] [CrossRef] [PubMed]
- Croxford, A.M.; Whittingham, S.; McNaughton, D.; Nandakumar, K.S.; Holmdahl, R.; Rowley, M.J. Type II collagen-specific antibodies induce cartilage damage in mice independent of inflammation. Arthritis Rheum. 2013, 65, 650–659. [Google Scholar] [CrossRef] [PubMed]
- Crombie, D.E.; Turer, M.; Zuasti, B.B.; Wood, B.; McNaughton, D.; Nandakumar, K.S.; Holmdahl, R.; van Damme, M.-P.; Rowley, M.J. Destructive effects of murine arthritogenic antibodies to type II collagen on cartilage explants in vitro. Arthritis Res. Ther. 2005, 7, R927–R937. [Google Scholar] [CrossRef] [PubMed]
- Uysal, H.; Bockermann, R.; Nandakumar, K.S.; Sehnert, B.; Bajtner, E.; Engström, A.; Serre, G.; Burkhardt, H.; Thunnissen, M.M.G.M.; Holmdahl, R. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 2009, 206, 449–462. [Google Scholar] [CrossRef] [PubMed]
- Hrncir, Z.; Tichỳ, M.; Salavec, M.; Vavrina, J. Immunoglobulins A, G, and M in synovial fluid in rheumatoid arthritis. Reactive synovitis of local origin and in post mortem synovial fluid. Ann. Rheum. Dis. 1972, 31, 325. [Google Scholar] [CrossRef] [PubMed]
- Levick, J. Synovial fluid dynamics: The regulation of volume and pressure. In Studies of Joint Disease; Maroudas, A., Holborow, E.J., Eds.; Pitman Books: London, UK, 1983; pp. 153–240. [Google Scholar]
- Huizinga, T.W.J.; Machold, K.P.; Breedveld, F.C.; Lipsky, P.E.; Smolen, J.S. Criteria for early rheumatoid arthritis. From Bayes’ law revisited to new thoughts on pathogenesis. Arthritis Rheum. 2002, 46, 1155–1159. [Google Scholar] [CrossRef] [PubMed]
- Ritchie, D.M.; Boyle, J.A.; McInnes, J.M.; Jasani, M.K.; Dalakos, T.G.; Grieveson, P.; Buchanan, W.W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q. J. Med. 1968, 37, 393–406. [Google Scholar] [PubMed]
- Larsen, A.; Dale, K.; Eek, M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol. Diagn. (Stockh) 1977, 18, 481–491. [Google Scholar] [CrossRef] [PubMed]
- Pinals, R.S.; Masi, A.T.; Larsen, R.A. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum. 1981, 24, 1308–1315. [Google Scholar] [CrossRef] [PubMed]
- Cook, A.D.; Stockman, A.; Brand, C.A.; Tait, B.D.; Mackay, I.R.; Muirden, K.D.; Bernard, C.C.; Rowley, M.J. Antibodies to type II collagen and HLA disease susceptibility markers in rheumatoid arthritis. Arthritis Rheum. 1999, 42, 2569–2576. [Google Scholar] [CrossRef]
- Sherritt, M.A.; Tait, B.; Varney, M.; Kanaan, C.; Stockman, A.; Mackay, I.R.; Muirden, K.; Bernard, C.C.; Rowley, M.J. Immunosusceptibility genes in rheumatoid arthritis. Hum. Immunol. 1996, 51, 32–40. [Google Scholar] [CrossRef]
- Rowley, M.; Tait, B.; Mackay, I.R.; Cunningham, T.; Phillips, B. Collagen antibodies in rheumatoid arthritis. Significance of antibodies to denatured collagen and their association with HLA-DR4. Arthritis Rheum. 1986, 29, 174–184. [Google Scholar] [CrossRef] [PubMed]
- Scott, P.G.; Veis, A. The cyanogen bromide peptides of bovine soluble and insoluble collagens. I. Characterization of peptides from soluble type I collagen by sodium dodecylsulphate polyacrylamide gel electrophoresis. Connect. Tissue Res. 1976, 4, 107–116. [Google Scholar] [CrossRef] [PubMed]
- Terato, K.; Cremer, M.A.; Hasty, K.A.; Kang, A.H.; Hasty, D.L.; Townes, A.S. Physicochemical and immunological studies of the renatured alpha 1(II) chains and isolated cyanogen bromide peptides of type II collagen. Coll. Relat. Res. 1985, 5, 469–480. [Google Scholar] [CrossRef]
- Medcalc Statistical Software. Available online: https://www.medcalc.org/ (accessed on 10 October 2016).
Early inflammatory Arthritis * | Longstanding Erosive RA | |||
---|---|---|---|---|
Remission | Persisting Non-Erosive | Erosive | ||
Number | 23 | 27 | 32 | 52 |
F:M (%F) | 13:10 (57%) | 14:13 (52%) | 25:7 (78%) | 36:16 (69%) |
Age at onset (years) | 71 (40–81) | 56 (25–81) | 58.5 (20–79) | 45.5 (25–74) |
Duration before presentation (months) | 3 (1–7) | 3 (0.5–7) | 3 (0.3–8) | - |
Duration before remission (months) | 12 (4–36) | - | - | - |
Duration of follow-up (years) | 4 (2–7) | 4 (2–10) | 5 (2–10) | 15 (2–61) |
Joints swollen at presentation | 7.5 (0–17) | 4 (1–22) | 9 (1–47) | |
Joints swollen 24 months | 0 (0–2) | 0 (0–14) | 3 (0–17) | |
Ritchie at presentation | 4.5 (2–9) | 4 (0–18) | 6 (2–21) | |
Ritchie 24 months | 0 (0–4) | 2 (0–16) | 3 (0–22) | |
ESR** at presentation | 39 (12–94) | 28 (1–82) | 38 (8–111) | |
ESR 24 months | 7.5 (1–112) | 14 (1–106) | 25 (1–76) | |
ARA criteria at presentation | 3 (1–5) | 4 (2–6) | 4 (1–7) | |
ARA criteria 24 months | 0.4 ± 0.8 (0–3) | 1 (0–5) | 3 (0–6) | |
Shared epitope (%) | 11/21 (52%) 2NT | 11/20 (55%) 7NT | 18/28(64%) 4NT |
Early Inflammatory Arthritis | Longstanding RA | Controls | |||
---|---|---|---|---|---|
Remission | Persisting Non-Erosive | Erosive | |||
Number | 23 | 27 | 32 | 52 | 136 |
Anti-CB10 | 20 (87%) | 18 (67%) | 24 (75%) | 34 (65%) | 6 (4%) |
Anti-CCP | 5 (22%) | 14 (52%) | 25 (78%) | 36 (69%) | 0 (0%) |
Rheumatoid factor | 7 (30%) | 18 (67%) | 22 (69%) | 35 (67%) | 12(9%) |
Number of antibodies (3:2:1:0) | 3:4:15:1 | 10:8:5:4 | 16:8:7:1 | 22:23:5:2 | 0:0:18:118 |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Whittingham, S.F.; Stockman, A.; Rowley, M.J. Collagen Autoantibodies and Their Relationship to CCP Antibodies and Rheumatoid Factor in the Progression of Early Rheumatoid Arthritis. Antibodies 2017, 6, 6. https://doi.org/10.3390/antib6020006
Whittingham SF, Stockman A, Rowley MJ. Collagen Autoantibodies and Their Relationship to CCP Antibodies and Rheumatoid Factor in the Progression of Early Rheumatoid Arthritis. Antibodies. 2017; 6(2):6. https://doi.org/10.3390/antib6020006
Chicago/Turabian StyleWhittingham, Senga F., Alex Stockman, and Merrill J. Rowley. 2017. "Collagen Autoantibodies and Their Relationship to CCP Antibodies and Rheumatoid Factor in the Progression of Early Rheumatoid Arthritis" Antibodies 6, no. 2: 6. https://doi.org/10.3390/antib6020006